Evidence map›Paper›PMID 37090505›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists.

Mahesh M Umapathysivam, Elisa Araldi, Benoit Hastoy, Adem Y Dawed, Hasan Vatandaslar, Shahana Sengupta, Adrian Kaufmann, Søren Thomsen, Bolette Hartmann, Anna E Jonsson and 22 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 15 institutions in 6 countries.

Mahesh M UmapathysivamOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Elisa AraldiInstitute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland.
Benoit HastoyOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Adem Y DawedDivision of Population Health & Genomics, School of Medicine, University of Dundee, UK.
Hasan VatandaslarInstitute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland.
Shahana SenguptaOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Adrian KaufmannInstitute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland.
Søren ThomsenOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Bolette HartmannDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University Copenhagen, Denmark.
Anna E JonssonCopenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
Hasan KabakciInstitute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland.
Swaraj ThamanDivision of Endocrinology, Department of Pediatrics, Stanford School of Medicine, Stanford, USA.
Niels GrarupCopenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
Christian T HaveCopenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
Kristine FærchDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University Copenhagen, Denmark.
Anette P GjesingCopenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
Sameena NawazOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Jane CheesemanOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Matthew J NevilleOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Oluf PedersenNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark.
Mark WalkerTranslational and Clinical Research Institute, Newcastle University, UK.
Christopher JennisonDepartment of Mathematics, University of Bath, UK.
Andrew T HattersleyUniversity of Exeter College of Medicine & Health, Exeter, UK.
Torben HansenNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark.
Fredrik KarpeOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Jens J HolstDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University Copenhagen, Denmark.
Angus G JonesUniversity of Exeter College of Medicine & Health, Exeter, UK.
Michael RistowInstitute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland.
Mark I McCarthyOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
Ewan R PearsonDivision of Population Health & Genomics, School of Medicine, University of Dundee, UK.
Markus StoffelInstitute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland.
Anna L GloynOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK.
ETH Zurich · CHSteno Diabetes Centers · DKUniversity of Oxford · GBChurchill Hospital · GBUniversity of Copenhagen · DKCentre for Human Genetics · GBNovo Nordisk Foundation · DKUniversity of Dundee · GBUniversity of Exeter · GBDiabetes Australia · AUJohannes Gutenberg University Mainz · DENewcastle University · GBStanford Medicine · USUniversity of Bath · GBUniversity of Zurich · CH

Funding

Bridging the gap between type 2 diabetes GWAS and therapeutic targetsUM1DK126185 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLAUSSNITZER, MELINA C, GLOYN, ANNA LOUISE · 2020 to 2024
$9.5M
Identifying variants causal for Type 2 Diabetes in Major human populationsU01DK085545 · NIDDK · UNIVERSITY OF OXFORD · PI CHAN, JULIANA CN, EBRAHIM, SHAH BRIAN · 2009 to 2013
$2.8M
Integrating genome-scale data to reveal causal mechanisms in type 2 diabetesU01DK105535 · NIDDK · UNIVERSITY OF OXFORD · PI GLOYN, ANNA LOUISE · 2015 to 2019
$1.7M
NIDDK NIH HHS U01 DK085545NIDDK NIH HHS U01 DK105535NIDDK NIH HHS UM1 DK126185Wellcome Trust 200837/Z/16/Z
6 · The paper itself

Abstract

Patients with type 2 diabetes vary in their response to currently available therapeutic agents (including GLP-1 receptor agonists) leading to suboptimal glycemic control and increased risk of complications. We show that human carriers of hypomorphic T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase

Identifiers

PMID37090505
PMCPMC10120798
OpenAlexW4365133573

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.